Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04224636
Title Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (DEMAND)
Acronym DEMAND
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ludwig-Maximilians - University of Munich
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.